Immunome (IMNM) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunome (IMNM) has outperformed Schrodinger (SDGR) over the past year, gaining 38.2% versus a gain of 35.4%. Over five years, IMNM leads with a +8.4% price change compared with -50.7% for SDGR. Immunome is the larger company by market cap ($2.25 billion vs $2.04 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | SDGR |
|---|---|---|
| Share price | $19.10 | $27.29 |
| Market cap | $2.25B | $2.04B |
| 1-day change | -1.11% | -5.57% |
| YTD return | -11.10% | +52.63% |
| 1-year return | +38.17% | +35.37% |
| 5-year return | +8.43% | -50.70% |
| EPS (TTM) | $-2.49 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.06 | $33.78 |
| 52-week low | $13.49 | $10.95 |
| Distance from 52-week high | -36.48% | -19.21% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +84.34% | -21.47% |
| Average volume | 1.19M | 1.69M |
| Shares outstanding | 118.00M | 65.64M |
| Employees | 247 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
IMNM vs SDGR FAQ
Which is bigger, Immunome or Schrodinger?
Immunome (IMNM) is larger, with a market capitalization of $2.25B compared with $2.04B for Schrodinger (SDGR).
Which stock has performed better over the past year, IMNM or SDGR?
IMNM returned +38.17% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.